Literature DB >> 21502194

Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back.

James R Halpert1.   

Abstract

This article reviews work from the author dating back to 1978 and focuses on the structural basis of cytochrome P450 (P450) function using available contemporary techniques. Early studies used mechanism-based inactivators that bound to the protein moiety of hepatic P450s to try to localize the active site. Subsequent studies used cDNA cloning, heterologous expression, site-directed mutagenesis, and homology modeling based on multiple bacterial P450 X-ray crystal structures to predict the active sites of CYP2B enzymes with considerable accuracy. Breakthroughs in engineering and expression of mammalian P450s enabled us to determine our first X-ray crystal structure of ligand-free rabbit CYP2B4. To date, we have solved 11 CYP2B4 and three human CYP2B6 structures, which represent four significantly different conformations. The plasticity of CYP2B4 has been confirmed by deuterium exchange mass spectrometry and is substantiated by molecular dynamics simulations. In addition to major movement of secondary structure elements, more subtle reorientation of active site side chains, especially Phe206, Phe297, and Glu301, contributes to the ability of CYP2B enzymes to bind various ligands. Isothermal titration calorimetry has proven to be a useful tool for studying the thermodynamics of ligand binding to CYP2B4 and CYP2B6, and NMR has enabled study of ligand binding orientation in solution as an adjunct to X-ray crystallography. A major challenge remains to harness the power of the various approaches to facilitate prediction of CYP2B specificity and inhibition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502194      PMCID: PMC3127236          DOI: 10.1124/dmd.111.039719

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  73 in total

Review 1.  Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications.

Authors:  Paul F Hollenberg; Ute M Kent; Namandjé N Bumpus
Journal:  Chem Res Toxicol       Date:  2007-12-04       Impact factor: 3.739

2.  Investigation of bioactivation of ticlopidine using linear ion trap/orbitrap mass spectrometry and an improved mass defect filtering technique.

Authors:  Qian Ruan; Mingshe Zhu
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

3.  Structures of cytochrome P450 2B4 complexed with the antiplatelet drugs ticlopidine and clopidogrel .

Authors:  Sean C Gay; Arthur G Roberts; Keiko Maekawa; Jyothi C Talakad; Wen-Xu Hong; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Biochemistry       Date:  2010-09-15       Impact factor: 3.162

4.  Covalent modification of Thr302 in cytochrome P450 2B1 by the mechanism-based inactivator 4-tert-butylphenylacetylene.

Authors:  Hsia-lien Lin; Haoming Zhang; Monica Jushchyshyn; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2010-03-03       Impact factor: 4.030

5.  Plasticity of cytochrome P450 2B4 as investigated by hydrogen-deuterium exchange mass spectrometry and X-ray crystallography.

Authors:  P Ross Wilderman; Manish B Shah; Tong Liu; Sheng Li; Simon Hsu; Arthur G Roberts; David R Goodlett; Qinghai Zhang; Virgil L Woods; C David Stout; James R Halpert
Journal:  J Biol Chem       Date:  2010-09-28       Impact factor: 5.157

Review 6.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.

Authors:  Hongbing Wang; Leslie M Tompkins
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

7.  Cooperative binding of acetaminophen and caffeine within the P450 3A4 active site.

Authors:  Michael D Cameron; Bo Wen; Arthur G Roberts; William M Atkins; A Patricia Campbell; Sidney D Nelson
Journal:  Chem Res Toxicol       Date:  2007-09-26       Impact factor: 3.739

8.  Crystal structures of cytochrome P450 2B4 in complex with the inhibitor 1-biphenyl-4-methyl-1H-imidazole: ligand-induced structural response through alpha-helical repositioning.

Authors:  Sean C Gay; Ling Sun; Keiko Maekawa; James R Halpert; C David Stout
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

9.  Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution.

Authors:  Sean C Gay; Manish B Shah; Jyothi C Talakad; Keiko Maekawa; Arthur G Roberts; P Ross Wilderman; Ling Sun; Jane Y Yang; Stephanie C Huelga; Wen-Xu Hong; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Mol Pharmacol       Date:  2010-01-08       Impact factor: 4.436

10.  Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.

Authors:  Katsunobu Hagihara; Yumi Nishiya; Atsushi Kurihara; Miho Kazui; Nagy A Farid; Toshihiko Ikeda
Journal:  Drug Metab Pharmacokinet       Date:  2008       Impact factor: 3.614

View more
  18 in total

1.  Crystal structure of human cytochrome P450 2D6 with prinomastat bound.

Authors:  An Wang; Uzen Savas; Mei-Hui Hsu; C David Stout; Eric F Johnson
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

2.  A model of the membrane-bound cytochrome b5-cytochrome P450 complex from NMR and mutagenesis data.

Authors:  Shivani Ahuja; Nicole Jahr; Sang-Choul Im; Subramanian Vivekanandan; Nataliya Popovych; Stéphanie V Le Clair; Rui Huang; Ronald Soong; Jiadi Xu; Kazutoshi Yamamoto; Ravi P Nanga; Angela Bridges; Lucy Waskell; Ayyalusamy Ramamoorthy
Journal:  J Biol Chem       Date:  2013-05-24       Impact factor: 5.157

Review 3.  Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges.

Authors:  Eric F Johnson; J Patrick Connick; James R Reed; Wayne L Backes; Manoj C Desai; Lianhong Xu; D Fernando Estrada; Jennifer S Laurence; Emily E Scott
Journal:  Drug Metab Dispos       Date:  2013-10-15       Impact factor: 3.922

4.  Inhibition of cytochrome P450 2B4 by environmentally persistent free radical-containing particulate matter.

Authors:  James R Reed; Albert Leo N dela Cruz; Slawo M Lomnicki; Wayne L Backes
Journal:  Biochem Pharmacol       Date:  2015-03-24       Impact factor: 5.858

Review 5.  Structural diversity of eukaryotic membrane cytochrome p450s.

Authors:  Eric F Johnson; C David Stout
Journal:  J Biol Chem       Date:  2013-04-30       Impact factor: 5.157

6.  Structural and biophysical characterization of human cytochromes P450 2B6 and 2A6 bound to volatile hydrocarbons: analysis and comparison.

Authors:  Manish B Shah; P Ross Wilderman; Jingbao Liu; Hyun-Hee Jang; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Mol Pharmacol       Date:  2015-01-13       Impact factor: 4.436

7.  Coumarin Derivatives as Substrate Probes of Mammalian Cytochromes P450 2B4 and 2B6: Assessing the Importance of 7-Alkoxy Chain Length, Halogen Substitution, and Non-Active Site Mutations.

Authors:  Jingbao Liu; Manish B Shah; Qinghai Zhang; C David Stout; James R Halpert; P Ross Wilderman
Journal:  Biochemistry       Date:  2016-03-24       Impact factor: 3.162

Review 8.  Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame.

Authors:  Sung-Mi Kim; YongQiang Wang; Noushin Nabavi; Yi Liu; Maria Almira Correia
Journal:  Drug Metab Rev       Date:  2016-06-20       Impact factor: 4.518

9.  So many roads traveled: A career in science and administration.

Authors:  James R Halpert
Journal:  J Biol Chem       Date:  2020-01-17       Impact factor: 5.157

10.  Functional characterization of cytochromes P450 2B from the desert woodrat Neotoma lepida.

Authors:  P Ross Wilderman; Hyun-Hee Jang; Jael R Malenke; Mariam Salib; Elisabeth Angermeier; Sonia Lamime; M Denise Dearing; James R Halpert
Journal:  Toxicol Appl Pharmacol       Date:  2013-12-19       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.